Translational Notes: Leukemia team building

 

Table 1. Programs on TAP. The Leukemia & Lymphoma Society (LLS) has partnered with academic institutions or biotech companies to fund the development of at least 14 therapeutics in preclinical through Phase III development via its Therapy Acceleration Program (TAP).

Source: BCIQ: BioCentury Online Intelligence; Leukemia & Lymphoma Society

Partner

Year

Compound name

Description

Indication

Clinical status

LLS commitment

University Health Network/BioTheryX Inc.A

2008

Ciclopirox

Repurposed small molecule antifungal

Hematological malignancies

Phase I

Undisclosed   

Celgene Corp.B

2010

CC-292

Small molecule Bruton's tyrosine kinase (Btk) inhibitor

B cell malignancies

Phase Ib

$3.2 M

Onconova Therapeutics Inc./Baxter International Inc. (NYSE:BAX)

2010

Rigosertib

Small molecule phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (PLK1; STPK13) inhibitor

Myelodysplastic syndrome (MDS)

Phase III

$12.5 M

Shape Pharmaceuticals Inc.

2010

SHP-141

Topical histone deacetylase (HDAC) inhibitor

Cutaneous T cell lymphoma (CTCL)

Phase I

$3.3 M

University of Colorado Denver

2011

Not applicable

Combination of cyclosporin A and tyrosine kinase inhibitor

Drug-resistant leukemia

Phase I

Undisclosed

Acetylon Pharmaceuticals Inc.C

2011

ACY-1215

Small molecule HDAC6 inhibitor

Multiple myeloma (MM)

Phase I

$5.6 M

Memorial Sloan-Kettering Cancer Center

2011

MSK-777

Small molecule inhibitor of cell division cycle 7-related protein kinase (CDC7)

Acute leukemias

Preclinical

Undisclosed

University of FloridaD

2011

Oxi4503

Combretastatin A1 diphosphate (CA1P) tubulin inhibitor

Acute myelogenous leukemia (AML)/MDS

Phase I

Undisclosed

Not applicable

2011

RI-BPI

Retro-inverso B cell CLL lymphoma 6 (BCL6) peptide inhibitor

Diffuse large B cell lymphoma (DLBCL)

Preclinical

Undisclosed

Curis Inc.

2011

CUDC-907

Small molecule dual PI3K and HDAC inhibitor

B cell lymphoma and MM

Preclinical

$4 M

University of Michigan Medical School

2012

Undisclosed

Small molecules that block the interaction of myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX) with multiple endocrine neoplasia I (MEN1; menin)

MLL

Preclinical

Undisclosed

The Johns Hopkins University School of Medicine

2012

PD-0332991

Small molecule inhibitor of cyclin dependent kinase 4 (CDK4) and CDK6

Acute leukemias/MDS

Phase I

Undisclosed

Celator Pharmaceuticals Inc.

2012

CPX-351

Liposomal formulation of cytarabine and daunorubicin

Secondary AML

Phase III

$5 M

Constellation Pharmaceuticals Inc.

2012

Undisclosed

Small molecule inhibitor of the bromodomain and extra terminal domain (BET) family of bromodomain-containing proteins

Hematological malignancies

Preclinical

$7.5 M

ALLS has a $4.5 M equity investment in BioTheryX. BProgram was known as AVL-292 prior to the purchase of Avila Therapeutics Inc. by Celgene in March 2012. Avila is now Celgene Avilomics. CAcetylon has received investment from Celgene. DOxi4503 is under development by OxiGene Inc. (NASDAQ:OXGN) for additional oncology indications.